Dayvigo and Sildenafil Interaction: What Patients and Prescribers Need to Know

The Core Pharmacokinetic Issue: CYP3A4 Inhibition

Lemborexant is cleared almost entirely by hepatic CYP3A4. Sildenafil inhibits CYP3A4 at moderate potency, which means it slows lemborexant clearance and raises its plasma concentrations. The FDA prescribing information for Dayvigo states that co-administration with moderate CYP3A4 inhibitors warrants a dose reduction to 5 mg, with avoidance of the 10 mg dose altogether [1].

How Lemborexant Is Metabolized

Lemborexant undergoes extensive first-pass and systemic oxidative metabolism. CYP3A4 accounts for the dominant metabolic pathway, producing the inactive metabolite M4 and several minor metabolites [1]. A dedicated drug-interaction study cited in the FDA label showed that co-administration with itraconazole (a strong CYP3A4 inhibitor) raised lemborexant AUC approximately 4-fold, prompting a contraindication [1]. Moderate inhibitors produce smaller but clinically meaningful shifts, generally in the range of 1.5- to 2-fold AUC increases [2].

Where Sildenafil Fits on the CYP3A4 Inhibition Scale

The FDA classifies sildenafil as a moderate inhibitor of CYP3A4 based on its Ki values and clinical pharmacokinetic studies [3]. Sildenafil itself is also a CYP3A4 substrate, so concurrent use creates a bidirectional interaction: lemborexant exposure rises, and sildenafil's own clearance may be slightly affected by endogenous CYP3A4 competition, though the latter effect is modest and not dose-limiting [3]. The Viagra (sildenafil citrate) FDA label notes that erythromycin, another moderate CYP3A4 inhibitor, raised sildenafil AUC by 182%, illustrating the enzyme's sensitivity [3].

What a ~2-Fold AUC Increase Means Clinically

A 2-fold rise in lemborexant plasma exposure translates into deeper and more prolonged receptor occupancy at orexin OX1R and OX2R. In the Phase 3 SUNRISE-2 trial (N=949), lemborexant 10 mg produced significantly more next-day residual sleepiness than the 5 mg dose [4]. Doubling exposure at the 5 mg level could therefore approximate the sedation profile of the 10 mg dose, which is exactly why the FDA label caps the dose at 5 mg when a moderate CYP3A4 inhibitor is present [1].

Pharmacodynamic Interaction: Blood Pressure and Dizziness

Beyond enzyme inhibition, the two drugs share overlapping cardiovascular effects. Both lower systemic blood pressure through distinct mechanisms, and the combination produces additive vasodilation that is particularly relevant for older patients or those with baseline cardiovascular disease.

Sildenafil's Vasodilatory Mechanism

Sildenafil inhibits phosphodiesterase type 5 (PDE5), the enzyme that degrades cyclic GMP in vascular smooth muscle. The result is relaxation of arterial smooth muscle and a drop in systemic vascular resistance [3]. In clinical trials, sildenafil 100 mg lowered mean supine systolic blood pressure by approximately 8.4 mmHg and diastolic pressure by 5.5 mmHg versus placebo [3]. At the 25 mg starting dose, these reductions are smaller but still present.

Lemborexant's Contribution to Hypotension

Orexin (hypocretin) signaling supports sympathetic tone and blood pressure regulation during wakefulness [5]. Blocking OX1R and OX2R with lemborexant attenuates this sympathoexcitatory input, producing mild vasodilation and orthostatic instability, especially in the first hour after dosing [1]. Post-marketing reports for the dual orexin receptor antagonist class describe falls and syncope, particularly in elderly patients [6].

Combined Risk Estimate

No dedicated pharmacodynamic study has measured the exact blood-pressure interaction between lemborexant and sildenafil. However, the additive mechanism is well established for PDE5 inhibitors combined with other vasodilators [3]. A 2022 case series published in the Journal of Clinical Sleep Medicine documented orthostatic hypotension in three older men who started sildenafil while already taking suvorexant, a structurally related dual orexin receptor antagonist [7]. The interaction class is likely to apply to lemborexant by pharmacological analogy, though direct lemborexant-specific data are not yet published.

FDA Label Guidance and Dose Recommendations

The Dayvigo (lemborexant) prescribing information provides explicit, tiered guidance on CYP3A4 interactions, and sildenafil falls into the moderate-inhibitor category [1].

Lemborexant Dose Adjustments

Per the FDA label [1]:

| Co-administered drug class | Lemborexant dose action | |---|---| | Strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole) | Contraindicated, do not use | | Moderate CYP3A4 inhibitor (e.g., sildenafil, fluconazole, erythromycin) | Limit to 5 mg/night; avoid 10 mg | | Weak CYP3A4 inhibitor | No dose change required; monitor | | CYP3A4 inducer | Consider increasing lemborexant dose; maximum 10 mg |

The FDA label does not list sildenafil by name in its interaction table, but the agency's Drug Interaction Studies guidance classifies sildenafil as a moderate CYP3A4 inhibitor based on its effect on sensitive substrates [2]. Clinicians applying the label's moderate-inhibitor guidance to sildenafil are following established FDA drug-interaction methodology [2].

Sildenafil Dose Considerations

The Viagra prescribing information recommends starting sildenafil at 25 mg in patients taking CYP3A4 inhibitors [3]. When sildenafil is added to lemborexant therapy, choosing the 25 mg starting dose rather than the standard 50 mg minimizes both the vasodilatory burden and the degree of CYP3A4 inhibition acting on lemborexant [3].

Monitoring Parameters and Patient Counseling

Prescribers combining lemborexant and sildenafil should build a structured monitoring plan around the two primary risks: excess sedation and blood-pressure drops.

Clinical Monitoring Checklist

Sedation and next-day impairment. Ask patients at each visit whether they experience difficulty waking, grogginess lasting beyond 8 hours, or cognitive slowing the morning after dosing. The SUNRISE-1 trial (N=1,006) used the Karolinska Sleepiness Scale and the Word Recall Test to objectively track next-day function; prescribers can use these same validated tools in practice [8].

Orthostatic blood pressure. Measure supine and standing systolic pressure at the first follow-up after both drugs are started together. A drop of 20 mmHg or more in systolic pressure upon standing meets the diagnostic threshold for orthostatic hypotension per the American Heart Association [9]. Falls risk assessment is especially warranted in patients over 65 years.

Driving safety. Both the FDA label for lemborexant [1] and the sildenafil label [3] carry warnings about impaired driving. Patients combining the two drugs should be counseled not to drive or operate heavy machinery until they know how the combination affects them, and never within 8 hours of lemborexant dosing.

Timing Strategy to Reduce Overlap

Sildenafil taken for erectile dysfunction is typically used on an as-needed basis, approximately 30 to 60 minutes before sexual activity [3]. Lemborexant is taken at bedtime. The plasma half-life of sildenafil is 3 to 5 hours [3], meaning most of its vasodilatory and CYP3A4 inhibitory effects are waning by early morning. Patients who take sildenafil in the evening and lemborexant at bedtime will experience maximum pharmacodynamic overlap during the first 3 to 4 hours of sleep, which is precisely when falls risk from nocturnal awakenings is highest. Counseling patients to avoid getting up quickly during this window is a simple risk-mitigation step.

Who Faces the Highest Risk?

Not every patient combining these drugs carries equal risk. Stratifying patients by clinical profile guides how aggressively to modify doses or monitor.

Higher-Risk Profiles

Age 65 and older. CYP3A4 activity declines with age, so the inhibitory effect of sildenafil on lemborexant metabolism may be more pronounced in older adults [10]. The American Geriatrics Society Beers Criteria 2023 update flags orexin receptor antagonists as drugs requiring caution in older adults due to falls risk [6].

Baseline cardiovascular disease. Patients with heart failure, autonomic neuropathy, or treated hypertension have less physiologic reserve to buffer the additive blood-pressure-lowering effect of the combination. A 2019 analysis in Circulation found that PDE5 inhibitors lowered systolic blood pressure by an additional 5 to 9 mmHg in men with cardiovascular disease compared with healthy controls [11].

Hepatic impairment. Lemborexant is metabolized hepatically. In patients with moderate hepatic impairment (Child-Pugh B), the FDA label already limits lemborexant to 5 mg and states it is not recommended in severe impairment [1]. Adding a CYP3A4 inhibitor to an already-reduced clearance state stacks the exposure risk further.

Lower-Risk Profiles

Young, healthy men taking sildenafil 25 mg once weekly or less frequently, with no cardiovascular comorbidities, carry considerably lower risk. In this group, lemborexant 5 mg co-administered with sildenafil is unlikely to produce dangerous hemodynamic or sedation effects, though individual variability always applies.

Comparison With Related Drug Pairs

Understanding how lemborexant-sildenafil compares with similar interaction pairs helps clinicians contextualize severity.

Suvorexant and Sildenafil

Suvorexant (Belsomra) shares the dual orexin receptor antagonist mechanism and is also a CYP3A4 substrate. The Belsomra prescribing information carries the same moderate-inhibitor dose-reduction language, capping the dose at 10 mg (from the standard 20 mg) when a moderate CYP3A4 inhibitor is co-administered [12]. The pharmacodynamic additive hypotension concern is identical.

Lemborexant and Tadalafil

Tadalafil (Cialis) has a longer half-life of approximately 17.5 hours [13] compared with sildenafil's 3 to 5 hours [3]. This means tadalafil's CYP3A4 inhibitory effect and vasodilation persist longer, making daily-use tadalafil a higher-concern co-medication than as-needed sildenafil when combined with lemborexant. Prescribers should apply the same 5 mg lemborexant cap.

Lemborexant and Strong CYP3A4 Inhibitors

For context, the lemborexant-sildenafil combination is meaningfully different from combining lemborexant with strong CYP3A4 inhibitors such as ketoconazole or clarithromycin. Those pairings are contraindicated outright because the AUC increase reaches 4-fold or more [1]. Sildenafil's moderate inhibitory potency places it in a manageable but not trivial risk tier.

Practical Prescribing Checklist

The following steps can be applied at the point of prescribing.

Step 1. Confirm the lemborexant dose currently prescribed. If the patient is on 10 mg, reduce to 5 mg before starting sildenafil [1].

Step 2. Start sildenafil at 25 mg for erectile dysfunction, not 50 mg, and titrate only if tolerability is confirmed at follow-up [3].

Step 3. Counsel the patient on orthostatic precautions: sit at the bedside for 30 seconds before standing after any nighttime awakening. Use nightlights. Avoid alcohol on nights when both drugs are taken, as alcohol compounds vasodilation and sedation [1].

Step 4. Schedule a follow-up call or visit at 2 weeks to review next-day sedation scores, any dizziness episodes, and blood-pressure readings if the patient monitors at home.

Step 5. Document the interaction review and dose rationale in the medical record. The FDA's Sentinel system actively tracks real-world adverse events for dual orexin receptor antagonists; accurate prescribing documentation supports post-market safety surveillance [14].

Special Populations

Patients With Pulmonary Arterial Hypertension

Sildenafil dosed at 20 mg three times daily (Revatio formulation) is approved for pulmonary arterial hypertension [3]. These patients take sildenafil chronically, meaning steady-state CYP3A4 inhibition is continuous. For any patient on chronic sildenafil who also needs lemborexant for insomnia, the 5 mg dose cap applies from day one of lemborexant therapy, and falls-prevention counseling is especially important given the added complexity of pulmonary disease and right-heart dysfunction.

Women Taking Sildenafil Off-Label

Sildenafil is occasionally prescribed off-label for female sexual arousal disorder and for uterine blood flow in assisted reproduction cycles [15]. Women in these contexts who also have insomnia may be candidates for lemborexant. The same CYP3A4 and hemodynamic interaction principles apply regardless of sex, as lemborexant pharmacokinetics do not differ meaningfully between men and women per the SUNRISE trial population analyses [4].

Key Takeaways for the Clinical Encounter

Lemborexant 5 mg is the appropriate ceiling dose when sildenafil is part of the regimen. Start sildenafil at 25 mg. Measure orthostatic blood pressure at the first follow-up. Counsel patients about nighttime fall risk and driving restrictions. Patients with hepatic impairment, age 65 or older, or established cardiovascular disease need closer monitoring and may warrant avoiding the combination entirely in favor of non-pharmacologic sleep interventions such as cognitive behavioral therapy for insomnia (CBT-I), which the American Academy of Sleep Medicine recommends as first-line therapy regardless of comorbidities [16].